Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Congress Wealth Management LLC DE

Congress Wealth Management LLC DE lessened its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 64.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,887 shares of the medical equipment provider’s stock after selling 5,242 shares during the period. Congress Wealth Management LLC DE’s holdings in Zimmer Biomet were worth $305,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in ZBH. Dunhill Financial LLC raised its holdings in Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares in the last quarter. Stonebridge Financial Group LLC acquired a new stake in Zimmer Biomet during the 4th quarter worth $25,000. Brooklyn Investment Group acquired a new stake in Zimmer Biomet during the 3rd quarter worth $35,000. Kentucky Trust Co purchased a new stake in Zimmer Biomet in the fourth quarter valued at $39,000. Finally, OFI Invest Asset Management acquired a new position in Zimmer Biomet in the fourth quarter valued at $40,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $112.21 on Friday. The company’s fifty day moving average is $107.18 and its two-hundred day moving average is $107.02. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The firm has a market capitalization of $22.34 billion, a P/E ratio of 25.22, a PEG ratio of 1.95 and a beta of 1.04. Zimmer Biomet Holdings, Inc. has a one year low of $97.69 and a one year high of $131.61.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter last year, the company earned $2.20 EPS. Analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.86%. Zimmer Biomet’s payout ratio is 21.57%.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares of the company’s stock, valued at $915,379.20. The trade was a 14.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.95% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Truist Financial reissued a “hold” rating and issued a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Barclays lowered their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research report on Monday, February 10th. JMP Securities reiterated a “market outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Raymond James decreased their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and an average price target of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.